Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
Author(s) |
Date | Article Title | Journal |
|---|---|---|---|
|
Hitesh B. Mistry, Gabriel Helmlinger, Nidal Al-Huniti, Karthick Vishwanathan, James Yates |
April 2019 | Resistance Models to EGFR Inhibition and Chemotherapy in Non-Small Cell Lung Cancer Via Analysis of Tumour Size Dynamics | Cancer Chemotherapy and Pharmacology |
|
Hiroyuki Saeki, Takuji Komeda, Risa Tanaka, Yuki Yamatani & Hironori Sakai |
March 2022 | Estimation of a Suitable Number of Patients for Selective Safety Data Collection (ICH E19 Draft Guideline): When is the Safety Profile of a Drug Well Characterized? | Therapeutic Innovation & Regulatory Science |
|
Hirotaka Miyashita, Christina Cruz, Vaibhav Patel |
August 2021 | Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate | Supportive Care in Cancer |
|
Hirotaka Miyashita, Christina Cruz, Stephen Malamud |
May 2020 | Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate | Breast Cancer Research and Treatment |
|
Hirotaka Miyashita, Christina Cruz, Cardinale Smith |
August 2020 | Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial | Supportive Care in Cancer |
|
Hani Oweira, Anway Giryes, Meinrad Mannhart, Michael Decker, and Omar Abdel-Rahman |
August 2018 | Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials | Expert Review of Gastroenterology and Hepatology |
|
H-G Eichler, B. Bloechl-Daum, P. Bauer, F. Bretz, J. Brown, LV Hampson, P. Honig, M. Krams, H. Leufkens, R. Lim, M.M. Lumpkin, M.J. Murphy, F. Pignatti, M. Posch, S. Schneeweiss, M. Trusheim, F. Koenig |
October 2016 | "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials? | Clinical Pharmacology & Therapeutics |
|
Guru Sonpavdea, Gregory R.Pond, Arnoud J.Templeton, Abderrahim Fandi, Bertrand Tombale, Mark Rosenthal, Andrew J.Armstrong, Daniel P.Petrylakh |
June 2016 | Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel | European Urology |
|
Giorgos Bakoyannis, Dipankar Bandyopadhyay |
November 2021 | Nonparametric tests for multistate processes with clustered data | AISM |
|
Gerd Rippin, Nicolás Ballarini, Héctor Sanz, Joan Largent, Chantal Quinten & Francesco Pignatti |
July 2022 | A Review of Causal Inference for External Comparator Arm Studies | Springer Nature Switzerland AG |
|
Geoffrey Fell, Robert A Redd, Alyssa M Vanderbeek, Rifaquat Rahman, Bill Louv, Jon McDunn, Andrea Arfè, Brian M Alexander, Steffen Ventz, Lorenzo Trippa |
June 2021 | KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials | Database |
|
Garrett S Bullock,Patrick Ward,Scott Peters, Amelia Joanna Hanford Arundale , Andrew Murray,Franco M Impellizzeri, Stefan Kluzek |
June 2022 | Call for open science in sports medicine | British Journal of Sports Medicine |
|
Ganessan Kichenadasse MBBS, FRACP, John O. Miners PhD, Arduino A. Mangoni MBBS, PhD, FRACP, Christos S. Karapetis MBBS, FRACP, Ashley M. Hopkins PhD and Michael J. Sorich PhD |
May 2021 | Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy | Journal of the National Comprehensive Cancer Network |
|
G. Sonpavde, G. R. Pond, A. J. Templeton, E. D. Kwon, J.S. De Bono |
June 2020 | Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases |
